Uninterrupted Clopidogrel Therapy Before Elective Colonoscopy Will Increase the Risk of Post-polypectomy Bleeding

• Status: Completed
• Trial end date: 2018-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This double-blind, randomized trial aims to evaluate whether uninterrupted anti-platelet therapy (clopidogrel) will increase the risk of bleeding associated with removal of polyp during colonoscopy in patients with coronary artery disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese University of Hong Kong
• Treatments: Clopidogrel; Ticlopidine

Criteria

Inclusion Criteria:

1. On regular treatment with clopidogrel alone or in combination with other anti-platelet drugs (e.g. aspirin)

2. Elective colonoscopy for asymptomatic screening of bowel cancer or investigation of bowel symptoms (e.g. altered bowel habit, rectal bleeding, anemia, polyp follow-up)

3. Age ≥ 18

4. Written informed consent

Exclusion Criteria:

1. Coronary stent of any type placed within 30 days

2. Cardiac-vascular event within 3 months

3. Drug-eluting coronary stent placed within 6 months

4. Terminal illness

5. Concomitant use of anticoagulants

6. Congenital or acquired bleeding diathesis showing clinical bleeding tendency (e.g. hemophilia, decompensated cirrhosis)

7. Pregnancy or women of child-bearing age without regular use of contraception